Version: 1.0.0 | Published: 8 Oct 2024 | Updated: 229 days ago
Documentation
Description:
Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease (UNIRAD).
Coverage
Spatial:
United Kingdom,England
Provenance
Temporal
Start Date:
01 January 2015
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
Institute of Cancer Research
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress